| Company | Adaptimmune Therapeutics |
| Stock Quote | NASDAQ: ADAP |
| Study Name | Afami-cel |
| Treatment | advanced synovial sarcoma |
| Status | Biologics License Application (BLA) |
| Catalyst Date | August 4, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Humacyte |
| Stock Quote | NASDAQ: HUMA |
| Study Name | Human Acellular Vessel |
| Treatment | Coronary Artery Bypass Grafting |
| Status | Biologics License Applications (BLA) Priority Review |
| Catalyst Date | August 10, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Citius Pharmaceuticals |
| Stock Quote | NASDAQ: CTXR |
| Study Name | LYMPHIR |
| Treatment | Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma |
| Status | Biologics License Application (BLA) |
| Catalyst Date | August 13, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | CymaBay Therapeutics |
| Stock Quote | NASDAQ: CBAY |
| Study Name | seladelpar |
| Treatment | for the Treatment of Primary Biliary Cholangitis Including Pruritus |
| Status | New Drug Application (NDA) |
| Catalyst Date | August 14, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Ascendis Pharma |
| Stock Quote | NASDAQ: ASND |
| Study Name | TransCon PTH |
| Treatment | Adult Hypoparathyroidism |
| Status | New Drug Application (NDA) |
| Catalyst Date | August 14, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Applied Therapeutics |
| Stock Quote | NASDAQ: APLT |
| Study Name | AT-007 |
| Treatment | Galactosemia |
| Status | New Drug Application (NDA) |
| Catalyst Date | August 28, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Syndax Pharmaceuticals |
| Stock Quote | NASDAQ: SNDX |
| Study Name | Axatilimab |
| Treatment | Chronic Graft Versus Host Disease (cGVHD) |
| Status | Biologics License Applications (BLA) Priority Review |
| Catalyst Date | August 28, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Travere Therapeutics |
| Stock Quote | NASDAQ: TVTX |
| Study Name | FILSPARI |
| Treatment | endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression |
| Status | supplemental New Drug Application (sNDA) |
| Catalyst Date | September 5, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Avadel Pharmaceuticals |
| Stock Quote | NASDAQ: AVDL |
| Study Name | LUMRYZ (sodium oxybate) |
| Treatment | extended-release sodium oxybate medication |
| Status | supplemental New Drug Application (sNDA) |
| Catalyst Date | September 7, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Iterum Therapeutics |
| Stock Quote | NASDAQ: ITRM |
| Study Name | sulopenem etzadroxil/probenecid |
| Treatment | Uncomplicated urinary tract infections (uUTIs) |
| Status | Phase 3 |
| Catalyst Date | September 9, 2024 |
| Catalyst | FDA Meeting |
| Announcement | Read More |
| Website | Click Here |
| Company | Heron Therapeutics |
| Stock Quote | NASDAQ: HRTX |
| Study Name | ZYNRELEF (bupivacaine and meloxicam HTX-011) |
| Treatment | Postoperative pain |
| Status | Phase 3 |
| Catalyst Date | September 23, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Merck |
| Stock Quote | NYSE: MRK |
| Study Name | KEYNOTE-483 |
| Treatment | for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. |
| Status | supplemental Biologics License Applications (sBLA) Priority Review |
| Catalyst Date | September 25, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Karuna Therapeutics |
| Stock Quote | NASDAQ: KRTX |
| Study Name | KarXT (xanomeline-trospium) |
| Treatment | Healthy Elderly Volunteers |
| Status | New Drug Application (NDA) |
| Catalyst Date | September 26, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Sanofi |
| Stock Quote | NASDAQ: SNY |
| Study Name | Dupixent (dupilumab) |
| Treatment | moderate-to-severe asthma |
| Status | supplemental Biologics License Applications (sBLA) |
| Catalyst Date | September 27, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Sanofi |
| Stock Quote | NASDAQ: SNY |
| Study Name | isatuximab |
| Treatment | Transplant-ineligible newly diagnosed multiple myeloma (NDMM). |
| Status | supplemental Biologics License Applications (sBLA) Priority Review |
| Catalyst Date | September 27, 2024 |
| Catalyst | PDUFA Date |
| Announcement | N/A |
| Website | Click Here |
| Company | NeuroOne Medical Technologies |
| Stock Quote | NASDAQ: NMTC |
| Study Name | ICD-10 |
| Treatment | sEEG RF Ablation |
| Status | N/A |
| Catalyst Date | October 1, 2024 |
| Catalyst | Data Presentation |
| Announcement | Read More |
| Website | Click Here |
| Company | PTC Therapeutics |
| Stock Quote | NASDAQ: PTCT |
| Study Name | Upstaza |
| Treatment | Aromatic L-amino acid decarboxylase (AADC) deficiency |
| Status | Biologics License Applications (BLA) |
| Catalyst Date | November 13, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Autolus Therapeutics |
| Stock Quote | NASDAQ: AUTL |
| Study Name | Obe-cel (AUTO1 - ALLCAR19) ALL |
| Treatment | Adult Acute lymphoblastic leukemia (ALL) |
| Status | N/A |
| Catalyst Date | November 16, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Applied Therapeutics |
| Stock Quote | NASDAQ: APLT |
| Study Name | AT-007 |
| Treatment | Galactosemia |
| Status | New Drug Application (NDA) |
| Catalyst Date | November 28, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | BridgeBio Pharma |
| Stock Quote | NASDAQ: BBIO |
| Study Name | Acoramidis (ATTRibute-CM) |
| Treatment | Symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) |
| Status | New Drug Application (NDA) |
| Catalyst Date | November 29, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Jazz Pharmaceuticals |
| Stock Quote | NASDAQ: JAZZ |
| Study Name | Zanidatamab |
| Treatment | In HER2+/HR+ Metastatic Breast Cancer |
| Status | Biologics License Applications (BLA) Priority Review |
| Catalyst Date | November 29, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | AstraZeneca |
| Stock Quote | NASDAQ: AZN |
| Study Name | Datopotamab deruxtecan (Dato-DXd) |
| Treatment | Hormone Receptor Positive |
| Status | Biologics License Applications (BLA) |
| Catalyst Date | December 20, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Checkpoint Therapeutics |
| Stock Quote | NASDAQ: CKPT |
| Study Name | Cosibelimab (cSCC) |
| Treatment | Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC) |
| Status | Biologics License Applications (BLA) |
| Catalyst Date | December 28, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Neurocrine Biosciences |
| Stock Quote | NASDAQ: NBIX |
| Study Name | crinecerfont |
| Treatment | For the Treatment of Congenital Adrenal Hyperplasia (CAH) |
| Status | New Drug Application (NDA) |
| Catalyst Date | December 30, 2024 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Bristol-Myers Squibb |
| Stock Quote | NYSE: BMY |
| Study Name | Opdivo (nivolumab) |
| Treatment | resected esophageal or gastroesophageal junction (GEJ) cancer in the adjuvant setting |
| Status | Phase 3 |
| Catalyst Date | February 28, 2025 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | Eton Pharmaceuticals |
| Stock Quote | NASDAQ: ETON |
| Study Name | ET-400 |
| Treatment | Hydrocortisone Oral Solution |
| Status | New Drug Application (NDA) |
| Catalyst Date | February 28, 2025 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
| Company | scPharmaceuticals |
| Stock Quote | NASDAQ: SCPH |
| Study Name | FUROSCIX |
| Treatment | Decompensated heart failure |
| Status | supplemental New Drug Application (sNDA) |
| Catalyst Date | March 6, 2025 |
| Catalyst | PDUFA Date |
| Announcement | Read More |
| Website | Click Here |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE